PCOS, a condition impacting millions of women worldwide, gets a new name

Rebranding PCOS: A New Name for a Complex Condition Affecting Millions of Women

PCOS a condition impacting millions of women – Polycystic ovarian syndrome, or PCOS, a widespread health issue impacting fertility and metabolic health, is set to undergo a significant rebranding. Experts argue that the condition, which affects up to 13% of women of reproductive age globally, has long been underdiagnosed due to its name. The World Health Organization (WHO) estimates that 70% of those affected remain unaware of their diagnosis. A recent study published in the Lancet proposes a new designation—polyendocrine metabolic ovarian syndrome (PMOS)—aimed at better reflecting its diverse symptoms and systemic impact.

From Cysts to Complexity: The Evolution of Understanding

Traditionally, PCOS has been associated with ovarian cysts, as implied by its name. However, the condition’s scope extends far beyond reproductive symptoms. According to the WHO, it is linked to irregular menstrual cycles, infertility, hair thinning, and a heightened risk of type 2 diabetes and cardiovascular disease. Dr. Helena Teede, an endocrinologist and professor of Women’s Health at Monash University, emphasized that the term “polycystic ovarian syndrome” has led to misconceptions, causing some patients to overlook its broader implications. Over her 25-year career, Teede has frequently encountered cases where the condition’s complexity was misunderstood, resulting in delayed diagnoses and suboptimal treatment.

“By calling this condition polycystic ovary, we’re missing the big picture,” said Dr. Alla Vash-Margita, an associate professor of obstetrics, gynecology, and reproductive sciences at Yale University. “There was a lot of stigma and myth related to this name. People thought they had large cysts, which they do not have.”

The Lancet paper, authored by Teede and her colleagues, marks the formal introduction of PMOS as a more precise term. The goal is to highlight the condition’s multisystem effects, which include hormonal imbalances, metabolic disturbances, and psychological factors. This shift aims to elevate its status from a perceived reproductive issue to a recognized systemic disorder. The paper’s lead author, Teede, explained that the new name emphasizes the endocrine system’s role in the condition, a key factor in its wide-ranging impacts.

Historical Context and Emerging Insights

Dr. Andrea Dunaif, a professor at the Icahn School of Medicine at Mount Sinai, traced the condition’s classification history. Initially identified as a reproductive disorder, PCOS was later linked to elevated male hormone levels, which disrupt menstrual regularity and fertility. By the 1980s, researchers discovered its connection to insulin resistance, a condition where the body fails to respond effectively to insulin. Dunaif noted that this resistance can force the body to produce more insulin, increasing the likelihood of diabetes development. Since then, studies have expanded PMOS’s profile, associating it with liver disease, heart conditions, and even neurological concerns like early dementia risk.

“The body has to produce more insulin, and if the body can’t kind of keep up with the needs, then diabetes can develop,” Dunaif said.

Recent findings have further complicated the condition’s characterization. Dr. Vash-Margita highlighted the inclusion of symptoms such as sleep apnea, depression, anxiety, and body dysmorphia, which underscore PMOS’s influence on both physical and mental health. The term “polyendocrine” in PMOS reflects this dual role, as the condition involves disruptions in the body’s endocrine system, a network of glands that regulate hormones. These disturbances can ripple through various organs and systems, making the condition’s impact far more profound than previously understood.

A Global Effort to Reframe the Narrative

The name change was the result of a 14-year initiative involving 56 patient and professional organizations worldwide. This collaborative effort sought to address the gaps in how PCOS is perceived and managed. Rachel Morman, Chair of Verity PCOS UK, stated in a news release that the rebranding would “reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is.”

While the gynecology field has largely acknowledged PMOS’s significance, the study authors believe other medical disciplines must also recognize its complexity. Teede argued that the condition’s metabolic and hormonal components require a multidisciplinary approach for effective care. For instance, endocrinologists, cardiologists, and mental health professionals may all play critical roles in addressing its various manifestations. The new name, they hope, will foster greater awareness and coordination across specialties.

Stigma and the Need for Clarity

Dr. Teede stressed that the old name contributed to stigma and misperceptions. Many patients, she noted, associate PCOS with visible ovarian cysts, ignoring its subtler, systemic effects. This misconception has led to treatment delays and a narrow focus on reproductive health, potentially overlooking related complications. The updated terminology aims to dispel these myths and promote a more holistic view of the condition.

Despite the optimism surrounding PMOS, some experts remain cautious. Dunaif suggested that the name might still fall short of capturing the condition’s full scope. She pointed out that family histories indicate PMOS could affect individuals without ovaries, highlighting its metabolic components as central to the diagnosis. Additionally, Dunaif proposed that further refinement could include subtypes, such as those primarily affecting reproduction versus those linked to metabolic factors.

Broader Implications for Patient Care

Researchers believe the name change will have tangible benefits. By emphasizing the endocrine and metabolic aspects, PMOS could encourage earlier intervention and more targeted therapies. This shift may also reduce the stigma surrounding the condition, prompting patients to seek comprehensive care. For example, cognitive decline, a concern tied to metabolic syndrome, might now be more closely linked to the new designation, underscoring the need for integrated approaches to treatment.

While the transition from PCOS to PMOS is not without challenges, the authors of the Lancet paper are confident it will reshape how the condition is understood and addressed. The rebranding represents a critical step toward acknowledging PMOS as a multifaceted disorder, one that requires attention from a wide range of medical professionals. As the name evolves, so too does the hope for improved diagnosis, treatment, and overall quality of life for those affected.